(Q43249735)

English

Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion

scientific article published on 3 November 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 November 2017

Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion (English)

1 reference

Europe PubMed Central

17 November 2017

1 reference

based on heuristic

inferred from title

lymphoblastic leukemia

1 reference

based on heuristic

inferred from title

Mieczyslaw Komarnicki

4

object named as

Mieczysław Komarnicki

1 reference

Europe PubMed Central

17 November 2017

Krzysztof Lewandowski

2

object named as

Krzysztof Lewandowski

1 reference

Europe PubMed Central

17 November 2017

1

object named as

Anna Czyz

1 reference

Europe PubMed Central

17 November 2017

author name string

Renata Kroll

3

1 reference

Europe PubMed Central

17 November 2017

publication date

3 November 2009

1 reference

Europe PubMed Central

17 November 2017

Medical Oncology

1 reference

Europe PubMed Central

17 November 2017

27

1 reference

Europe PubMed Central

17 November 2017

4

1 reference

Europe PubMed Central

17 November 2017

1123-1126

1 reference

Europe PubMed Central

17 November 2017

https://scigraph.springernature.com/pub.10.1007/s12032-009-9347-0

0 references

The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19885746

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

1 reference

https://pubmed.ncbi.nlm.nih.gov/19885746

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19885746

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19885746

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19885746

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19885746

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19885746

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

1 reference

https://pubmed.ncbi.nlm.nih.gov/19885746

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19885746

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19885746

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19885746

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19885746

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19885746

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19885746

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

1 reference

https://pubmed.ncbi.nlm.nih.gov/19885746

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dasatinib-induced restoration of donor chimerism in BCR-ABL1-positive ALL after failure of imatinib therapy and allo-SCT.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19885746

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19885746

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19885746

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL

1 reference

https://pubmed.ncbi.nlm.nih.gov/19885746

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12032-009-9347-0

1 reference

Europe PubMed Central

17 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

17 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43249735&oldid=1984858924"